Altimmune Statement on the Passing of Dr. Stephen Harrison
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – ALT
The recorded move for ALT in the trading session of this news was +0.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing.
Dr. Harrison’s countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were only rivaled by his eloquence, charisma and steadfast commitment to improving the lives of people with liver disease. He was a tireless advocate for patients and a deeply respected advisor, investigator and friend to Altimmune.
We will miss him greatly as we adjust to this tremendous loss for the community. We honor his memory and are grateful for having known and worked with him.
Contact:
Rich Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
